Advertisement
Advertisement
Havrix 1440 Adult

Havrix 1440 Adult

hepatitis a vaccine

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Inactivated HAV HM175 strain
Indications/Uses
Active immunisation against HAV infection in subjects at risk of exposure to HAV.
Dosage/Direction for Use
IM Primary immunisation Adult ≥19 yr 1 mL single dose in deltoid area. Booster vaccination After primary vaccination, booster dose should be given between 6 mth & 5 yr, but preferably between 6 & 12 mth after primary dose.
Contraindications
Hypersensitivity to the vaccine or after previous inj.
Special Precautions
Not to be inj SC, intravascularly, intradermally or in the gluteal region. Not for prevention against infection caused by other agents eg, HBV, HCV, hepatitis E virus or other pathogens infecting the liver. Postpone vaccination in patients w/ acute severe febrile illness. Thrombocytopenia or bleeding disorder; syncope. Patients w/ impaired immune system. Patients undergoing haemodialysis. Pregnancy & lactation.
Adverse Reactions
Irritability; headache; inj site pain & redness, fatigue. Loss of appetite; drowsiness; GI symptoms eg, diarrhoea, nausea, vomiting; malaise, fever (≥37.5°C), inj site swelling or induration.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BC02 - hepatitis A, inactivated, whole virus ; Belongs to the class of hepatitis viral vaccines.
Presentation/Packing
Form
Havrix 1440 Adult vaccine (inj)
Packing/Price
1 mL x 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement